SeaStar Medical (ICU) announces the activation of Sentara Norfolk General Hospital in Norfolk, Virginia as its thirteenth active site in its NEUTRALIZE-AKI pivotal trial. The Company also reports the enrollment of nine critically ill adult acute kidney injury, AKI, patients in the trial during November, bringing total trial enrollment to 65 subjects. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company’s proprietary therapeutic Selective Cytopheretic Device, SCD, in 200 adult patients with AKI in the intensive care unit, ICU, receiving continuous renal replacement therapy, CRRT.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICU:
- SeaStar announces two advisory firms recommended vote favor of proposals
- SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device
- Seastar Medical Faces Distribution Challenges with Self-Marketing of QUELIMMUNE
- ICU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- SeaStar Medical announces BDD from U.S. FDA CBER for SCD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
